LUTETIUM LU 177 DOTATATE pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Start Trial	2023-05-5H06497	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 30, 2025

Introduction

Lutetium Lu 177 DOTATATE (Lutetium Lu 177 DOTA-TATE) is a targeted radioligand therapy primarily used for treating somatostatin receptor-positive neuroendocrine tumors (NETs). Its significance in precision oncology enhances the importance of reliable API sourcing. As the therapeutic efficacy hinges on high-purity, consistent API supply, understanding the current bulk API landscape is critical for pharmaceutical manufacturers, healthcare providers, and investors seeking stable collaborations or investment opportunities.

Overview of Lutetium Lu 177 Dotatate

Lutetium Lu 177 DOTATATE combines the radionuclide Lutetium-177 (Lu-177) with the peptide DOTA-TATE, which binds selectively to somatostatin receptors expressed on neuroendocrine tumor cells. The isotope Lu-177 provides beta radiation for targeted destruction, while DOTA functions as a chelator. The API synthesis involves the preparation of Lu-177-labeled DOTA-TATE, requiring stringent radiochemical and chemical standards.

Global Supply Chain Landscape

The supply chain of Lutetium Lu 177 DOTATATE's API is complex, involving multiple specialized components:

Lutetium-177 Radioisotope Production: This is the foundational step, typically generated via cyclotron or reactor-based methods, using enriched ytterbium or hafnium targets.
Peptide Manufacturing: Synthesis of DOTA-TATE peptide involves solid-phase peptide synthesis with high stereochemical purity.
Radionuclide Labeling: Incorporation of Lu-177 into DOTA-TATE must meet pharmaceutical-grade radiolabeling standards, often conducted in GMP facilities.

Major API suppliers and manufacturers operate across North America, Europe, and Asia, with a few institutions dominating due to the specialized nature of isotope production and peptide synthesis.

Key API Sources for Lutetium Lu 177 Dotatate

1. Cyclotron and Reactor-Based Isotope Producers

The core of Lutetium Lu 177 DOTATATE relies fundamentally on the high-purity generator-grade Lu-177 isotope. Major suppliers of Lu-177 include:

ITG Isotope Technologies Garching (Germany):
A leading supplier of Lu-177, primarily produces reactor-derived Lu-177 with high radiochemical purity suitable for therapeutic applications. Their isotope conforms to GMP standards, facilitating seamless API formulation.
Isotopen Technologien München (ITM) Laboratories (Germany):
ITM offers Lu-177 generators and bulk radiolabeled compounds, with a focus on personalized medicine applications. They supply Lu-177 with high specific activity, ensuring efficient radiolabeling of DOTA-TATE.
PerkinElmer (USA):
Offers cyclotron-produced Lu-177, primarily for research and clinical use, with increasing commercial production capacity aligned with regulatory standards for therapeutic radiopharmaceuticals.
Nihon Medi-Physics (Japan):
Provides Lu-177 derived via reactor methods, with a focus on local markets in Asia and evolving regulatory compliance for pharmaceutical-grade API.

2. Peptide API Manufacturers

The peptide component, DOTA-TATE, is synthesized by specialized peptide API manufacturers:

Bachem (Switzerland, USA):
A global leader in peptide synthesis, Bachem supplies GMP-grade DOTA-TATE peptides suitable for radiolabeling. Their extensive manufacturing facilities ensure high batch-to-batch consistency.
JPT Peptide Technologies (Germany):
Offers high-quality peptide APIs, including DOTA-TATE, with flexible scale-up options and GMP certification.
Peptide Center (India):
Growing presence in peptide API manufacturing, offering cost-effective DOTA-TATE peptides, although with varying GMP compliance levels, requiring validation for radiopharmaceuticals.

3. Radiolabeling Service Providers

While some pharmaceutical companies manufacture their own Lu-177 DOTA-TATE API, several radiopharmacies and CROs offer radiolabeling services:

Premier Radiopharmaceutical Manufacturing (USA):
Provides GMP-grade Lu-177 radiolabeling services, effectively acting as API suppliers for downstream formulations.
Bracco Imaged (\text{Known for}) iohexol and other radiopharmaceuticals:
Offers radiopharmaceutical manufacturing services, including Lu-177 labeled compounds.

Emerging Trends and Future API Supply Considerations

Intermittent Supply Risks:
Because of the complexity in Lu-177 production (reactor availability, target material sourcing), disruptions can impact API availability. The reliance on aging reactor infrastructure, such as those in Europe and Japan, presents ongoing supply risks.
Supply Chain Diversification:
To mitigate risks, pharmaceutical companies seek multiple API sources. Notably, the advent of cyclotron-based Lu-177 production offers a promising alternative to reactor-derived isotope.
Regulatory Approvals and Quality Standards:
API sources must meet stringent GMP standards and possess comprehensive quality documentation, including radiochemical purity, specific activity, and stability data consistent with ICH Q7 and other pharmaceutical guidelines.
Strategic Partnerships:
Major pharmaceutical firms often collaborate directly with isotope producers or peptide manufacturers to ensure consistent supply. Vertical integration—ranging from isotope procurement to API formulation—is increasingly prevalent.

Key Challenges in API Acquisition for Lutetium Lu 177 Dotatate

Radioisotope Shortages:
Current reliance on nuclear reactors limits supply expansion. The closure or aging of reactors impairs regional availability.
GMP Compliance:
Not all isotope producers can deliver GMP-grade Lu-177, narrowing options for pharmaceutical-grade APIs.
Cost and Scalability:
The high costs associated with isotope production and peptide synthesis pressure the pricing structure for DOTA-TATE API, affecting overall treatment costs.
Logistics and Handling:
The radioactive nature of Lu-177 necessitates specialized logistics for safe transportation, storage, and handling, complicating international sourcing.

Conclusion

The supply landscape for Lutetium Lu 177 Dotatate API involves a limited number of specialized suppliers capable of delivering high-purity, GMP-grade isotope and peptide components. Leading isotope producers such as ITG and ITM dominate the global Lu-177 landscape, while peptide manufacturers like Bachem serve as critical suppliers for the chelating peptide. The evolution toward cyclotron-produced Lu-177 promises to diversify supply, potentially reducing dependence on aging reactors. Strategic partnerships and supply chain resilience are essential to ensure stable access to high-quality API vital for the production of Lutetium Lu 177 Dotatate therapies.

Key Takeaways

The core of Lutetium Lu 177 Dotatate API relies on high-purity Lu-177 isotope and GMP-grade DOTA-TATE peptide, with few global suppliers due to technical complexity.
Most isotope production occurs at specialized nuclear facilities in Europe and Japan, with emerging cyclotron-based methods enhancing supply stability.
Peptide API manufacturers, such as Bachem, provide consistent GMP-grade DOTA-TATE essential for radiolabeling.
Disruptions in reactor availability, regulatory hurdles, and logistical challenges highlight the importance of diversification and strategic sourcing.
Collaboration between isotope producers, peptide manufacturers, and radiopharmaceutical companies is key to ensuring supply continuity for this targeted therapy.

5 FAQs

Q1: What are the primary challenges in sourcing Lutetium Lu 177 for API production?
A1: The main challenges include limited reactor-based isotope production capacity, reliance on aging nuclear infrastructure, regulatory requirements for GMP-grade Lu-177, and logistical complexities related to radioactive material handling.

Q2: Which regions dominate the supply of Lutetium Lu 177 API?
A2: Europe (notably Germany), Japan, and North America are key regions with established reactor or cyclotron-based isotope production facilities. Asia is expanding its capacity, particularly in Japan and India.

Q3: How does cyclotron-produced Lu-177 compare with reactor-produced isotope?
A3: Cyclotron-produced Lu-177 offers a potentially more flexible and regional production method, reducing dependence on nuclear reactors and possibly improving supply stability. However, it still requires high-specific-activity production and regulatory approval.

Q4: Are there alternative radiolabeled peptides or isotopes for similar therapeutic applications?
A4: Yes. Alternatives include therapies using different radionuclides like Actinium-225, or peptides targeting other receptors, but Lutetium Lu 177 DOTATATE remains the standard for specific neuroendocrine tumors.

Q5: What are the considerations for pharmaceutical companies when securing Lutetium Lu 177 API?
A5: They must assess purity, specific activity, GMP compliance, supply reliability, and logistical factors. Establishing long-term partnerships with reliable isotope producers and peptide manufacturers is crucial to ensure uninterrupted production.

Sources

[1] International Atomic Energy Agency (IAEA). "Design and Licensing of Radiopharmaceutical Production."
[2] PerkinElmer. "Lu-177 for Radiopharmaceutical Applications."
[3] Bachem. "GMP-grade Peptides for Targeted Radiotherapy."
[4] ITM Molecular Imaging. "Lu-177 Production and Supply."
[5] Nuclear Pharmacy News. "Current Developments in Isotope Production."

Bulk Pharmaceutical API Sources for LUTETIUM LU 177 DOTATATE